Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Alnylam will pay Isis for Takeda deal

Alnylam will pay Isis for Takeda deal

29th May 2008

Isis Pharmaceuticals will receive a payment of $4.6 million (2.4 million pounds) in upfront fees from Alnylam for its transaction with Takeda, it has announced.

Future milestone and royalty payments could also be made for an agreement made between it and Alnylam for the exclusive rights to Isis intellectual property ? namely double-stranded oligonucleotide therapeutics that mediate RNAi.

Alnylam and Takeda said they have formed a strategic partnership to develop RNAi therapeutics in the fields of oncology and metabolic disease, according to Thomson Financial News (TFN).

Isis owns or controls more than 1,500 drug patents and has made more than $1 million in licensing fees.

Stan Crooke, chairperson and chief executive of Isis said the company’s innovation has created a firm foundation for exploiting its patents.

“Isis has benefited substantially from Alnylam’s business development and financial successes,” he added.

“We look forward to additional successes from this valuable strategic relationship.”

According to TFN, Isis shares rose 3.3 per cent to $13.05 in early trading on Wednesday.

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.